Metraipolis › archive › dc_cf11722fd0bc

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility — Europe PMC PMID:42654399

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42654399
DOI
10.3390/medicina62081502
License (as archived)
solo-consultazione
Archived
2026-10-17T03:08:43.550Z
SHA-256 of the archived text
2cae0767f9bba1f27726d8e886db2e4712aa8f02004fe04f84ba089966b25da6
Stable URL of this page
https://metraipolis.com/documento/dc_cf11722fd0bc

How to cite

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility — Europe PMC PMID:42654399 — Europe PMC (en), https://europepmc.org/article/MED/42654399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf11722fd0bc (Metraipolis archive dc_cf11722fd0bc, sha256 2cae0767f9bba1f27726d8e886db2e4712aa8f02004fe04f84ba089966b25da6)
BibTeX
@misc{dccf11722fd0bc,
  title = {BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility — Europe PMC PMID:42654399},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42654399},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf11722fd0bc; sha256 2cae0767f9bba1f27726d8e886db2e4712aa8f02004fe04f84ba089966b25da6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42654399. Agents can read the archived copy with the MCP tool read_document.